Atsushi Iwata

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 216 publications

Projected lecanemab wastage from vial discard: Simulation based on Japanese interim post-marketing surveillance summary statistics.

Projected lecanemab wastage from vial discard: Simulation based on Japanese interim post-marketing surveillance summary statistics.

Journal: Journal of Alzheimer's disease : JAD

Published: July 21, 2026

SWI and T2*-GRE Microhemorrhage Counts in Anti-Amyloid Therapy Eligibility: A Real-World-Calibrated Simulation Study.

SWI and T2*-GRE Microhemorrhage Counts in Anti-Amyloid Therapy Eligibility: A Real-World-Calibrated Simulation Study.

Journal: medRxiv : the preprint server for health sciences

Published: July 03, 2026

Potential and biases of large language model simulation for public surveys on Alzheimer's disease therapies.

Potential and biases of large language model simulation for public surveys on Alzheimer's disease therapies.

Journal: Journal of Alzheimer's disease : JAD

Published: June 27, 2026

MMSE-CDR-SB residual as an exploratory indicator of deviation from an Alzheimer's disease-typical cognitive-functional pattern.

MMSE-CDR-SB residual as an exploratory indicator of deviation from an Alzheimer's disease-typical cognitive-functional pattern.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: May 23, 2026

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial.

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial.

Journal: Neurology. Clinical practice

Published: May 13, 2026

Early-onset Alzheimer's disease with PSEN1 G206D mutation presenting with amnesia at an onset age of 29 years old

Early-onset Alzheimer's disease with PSEN1 G206D mutation presenting with amnesia at an onset age of 29 years old

Journal: Rinsho shinkeigaku = Clinical neurology

Published: April 12, 2026

Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapy.

Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapy.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: February 27, 2026

Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study.

Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study.

Journal: The journal of prevention of Alzheimer's disease

Published: January 20, 2026

Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer's disease.

Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer's disease.

Journal: The journal of prevention of Alzheimer's disease

Published: January 18, 2026

Reframing dementia care in the era of disease-modifying therapies: informational, psychosocial, and systemic insights from Japan.

Reframing dementia care in the era of disease-modifying therapies: informational, psychosocial, and systemic insights from Japan.

Journal: BMC health services research

Published: January 14, 2026

ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab.

ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab.

Journal: The journal of prevention of Alzheimer's disease

Published: January 11, 2026

Seed Amplification Assays for Parkinson's Disease: A Review of α-Synuclein Assays in Body Fluids and Tissues.

Seed Amplification Assays for Parkinson's Disease: A Review of α-Synuclein Assays in Body Fluids and Tissues.

Journal: Journal of neurochemistry

Published: December 11, 2025

Showing 1-12 of 216

Last Updated: 09/26/2026